Literature DB >> 31126513

Recognition and Management of Medication Excipient Reactivity in Patients With Mast Cell Activation Syndrome.

Jill R Schofield1, Lawrence B Afrin2.   

Abstract

Mast cell activation syndrome (MCAS) is a complex disorder hallmarked by chronic multisystem inflammatory, allergic and growth dystrophic phenomena caused by inappropriate mast cell activation. MCAS has been estimated to affect as many as 17% of the population with a severity ranging from mild to life-threatening. MCAS patients are more sensitive than the average person to chemicals in the environment, including the nondrug ("inactive") ingredients (excipients) in medications and supplements. Excipient reactivity may explain unusual side effects to medications health professionals often find puzzling, such as the patient who appears intolerant of prednisone, acetaminophen, levothyroxine, or a vitamin. We present a series of patients with MCAS to illustrate important points regarding excipient reactivity which may be useful in everyday practice.
Copyright © 2019 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemical sensitivity; Ehlers-Danlos syndrome; Excipient; Mast cell activation syndrome; Postural tachycardia syndrome

Mesh:

Substances:

Year:  2019        PMID: 31126513     DOI: 10.1016/j.amjms.2019.03.005

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  1 in total

1.  Post-HPV-Vaccination Mast Cell Activation Syndrome: Possible Vaccine-Triggered Escalation of Undiagnosed Pre-Existing Mast Cell Disease?

Authors:  Lawrence B Afrin; Tania T Dempsey; Leonard B Weinstock
Journal:  Vaccines (Basel)       Date:  2022-01-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.